Although Novo Nordisk has been struggling for over a year, the relative discount may attract bullish speculators to NVO stock ...

Lilly's weight-loss medications Mounjaro and Zepbound are gaining market share on Novo's Wegovy and Ozempic, but investors ...

Viking Therapeutics stock tumbled after the drugmaker released study results of its experimental weight-loss pill.

Novo Nordisk (NYSE: NVO) stock is up 2.2% through 10:30 a.m. ET on Viking's bad news. Where to invest $1,000 right now? Our ...

Novo Nordisk's (NVO) corrections amid AI market rotation might be an opportunity, due to GLP-1 market leadership & balanced ...

A Comeback Fueled by Resilience Danish pharmaceutical giant Novo Nordisk (NYSE:NVO) has been a trailblazer in the GLP-1 drug ...

Novo Nordisk A/S gains momentum with FDA approval for Wegovy and strategic pricing. Click for why Novo outshines Eli Lilly ...

Wegovy-maker Novo Nordisk has implemented a global hiring freeze covering job roles that are not critical for its business, ...

No one stays on top forever. It’s a lesson that Ozempic maker Novo Nordisk may be painfully learning about. The Danish ...

Through innovation, cost discipline, legal action, and competitive pricing, Novo Nordisk has reasserted its leadership in the GLP-1 market. With a robust pipeline and global expansion, NVO is poised ...

A closer look at today's Trending Tickers - the stocks making the biggest moves worldwide - including Eli Lilly (LLY), Novo ...

Novo Nordisk and Eli Lilly (NYSE:LLY) shares edged higher Tuesday following results from Viking Therapeutics’ Phase 2 VENTURE-Oral Dosing trial for its oral obesity treatment.